AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
InterCure Ltd. (NASDAQ:INCR)
0.94 USD
+0.033 3.616%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.9072 |
|---|---|
| Change | +0.033 3.616% |
| 52 W H/L (in USD) | 3.720/0.990 |
| EBITDA (in USD) | 6.681M |
| PE Ratio | -- |
| Volume | 12001 |
| Diluted Eps TTM | -0.38 |
| Total Assets (in USD) | 786.614M |
|---|---|
| Total Liabilities (in USD) | 329.552M |
| Revenue TTM (in USD) | 355.553M |
| Cash (in USD) | 101.139M |
| Market Cap (in USD) | 149.478 M |
| Revenue Per Share TTM | 7.802 |
| Gross Profit TTM (in USD) | 102.563M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
INC Research Holdings Inc
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Employees: 270
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Alexander Rabinovitch | CEO & Director | 1971 |
| 2. | Mr. Amos Cohen | Chief Financial Officer | 1979 |
| 3. | Mr. Rami Levy | Chief Operating Officer of Canndoc | 1965 |
| 4. | Mr. Omri Batzir | Corp. Controller | NA |
| 5. | Advocate Asaf Ohayon | Co-Founder & Co-CEO of Cannolam Ltd. | 1989 |
| 6. | Mr. Ori-Moni Mimon | Co-Founder & Co-CEO of Cannolam Ltd. | 1988 |
| 7. | Mr. Alexander Rabinovich | CEO & Director | 1971 |
| 8. | Einat Zehavi | Vice President of Sales | NA |
| 9. | Mr. Omri Batzir | Corporate Controller | NA |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ZTS
Zoetis Inc |
-1.160 1.540% | 75.78 | 40.180 | 30.960 | 10.675 | 17.597 | 11.271 | 26.180 |
|
MKKGY
Merck KGaA ADR |
+0.490 1.593% | 31.55 | 21.250 | 14.925 | 3.099 | 2.143 | 3.605 | 12.978 |
|
MKGAF
MERCK Kommanditgesellschaft auf Aktien |
0.000 0.000% | 154.7 | 21.730 | 14.948 | 3.159 | 2.147 | 3.562 | 12.822 |
|
GALDY
GALDERMA GROUP AG |
-0.480 1.113% | 43.38 | 74.210 | 41.667 | 8.636 | 5.553 | 9.151 | 42.220 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 43.842M | 18.737M | -38.308M | -3.669M | -12.798M |
| Minority Interest | 1.07M | -2.603M | 17.603M | 0.229M | 0.229M |
| Net Income | 44.819M | 7.296M | -36.04M | -2.996M | -12.798M |
| Selling General Administrative | 91.721M | 30.725M | 17.856M | 76.359M | 9.81M |
| Gross Profit | 155.083M | 91.131M | 31.975M | 1.479M | - |
| Reconciled Depreciation | 11.699M | 7.393M | 3.253M | 0.023M | 0.01M |
| Ebit | 52.802M | 28.188M | -1.448M | -80.136M | -8.171M |
| Ebitda | 64.501M | 37.579M | 1.805M | -21.204M | -8.161M |
| Depreciation And Amortization | 11.699M | 9.391M | 3.253M | 58.932M | 0.01M |
| Operating Income | 52.802M | 28.188M | -1.448M | -80.136M | -10.622M |
| Other Operating Expenses | 335.755M | 186.651M | 61.677M | 89.062M | 9.81M |
| Interest Expense | 14.689M | 5.045M | 0.264M | 1.838M | 1.026M |
| Tax Provision | 0.093M | 11.441M | -2.268M | -0.673M | - |
| Interest Income | 0.844M | 0.13M | 0.021M | 0.141M | 0M |
| Net Interest Income | -13.845M | -4.915M | -0.507M | -1.831M | -1.037M |
| Income Tax Expense | 0.093M | 11.441M | -2.268M | -0.673M | -1.15M |
| Total Revenue | 388.684M | 219.677M | 65.035M | 8.926M | 0M |
| Total Operating Expenses | 102.154M | 58.105M | 28.617M | 81.615M | 9.81M |
| Cost Of Revenue | 233.601M | 128.546M | 33.06M | 7.447M | - |
| Total Other Income Expense Net | -8.96M | -9.451M | -36.86M | 76.467M | -1.951M |
| Net Income From Continuing Ops | 43.749M | 7.296M | -36.04M | -2.996M | -12.798M |
| Net Income Applicable To Common Shares | - | 4.692M | -37.231M | -5.893M | -12.798M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 786.614M | 958.007M | 686.324M | 326.27M | 282.233M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 151.785M | 18.251M | 34.202M | 0.829M | 1.145M |
| Total Liab | 329.552M | 436.53M | 227.13M | 34.161M | 26.032M |
| Total Stockholder Equity | 455.112M | 501.305M | 448.031M | 274.506M | 255.972M |
| Other Current Liab | 4.082M | 46.218M | 50.622M | 7.539M | 3.852M |
| Common Stock | 643.158M | 632.025M | 623.565M | 452.259M | 403.4M |
| Capital Stock | 643.158M | 632.025M | 623.567M | 452.259M | 403.4M |
| Retained Earnings | -203.995M | -141.649M | -186.466M | -191.158M | -151.03M |
| Good Will | 221.08M | 284.181M | 258.07M | 190.103M | 167.965M |
| Other Assets | - | - | 3.021M | 2.904M | - |
| Cash | 101.139M | 232.589M | 196.217M | 37.888M | 27.338M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 225.868M | 312.719M | 193.583M | 29.877M | 22.633M |
| Current Deferred Revenue | 50.512M | 8.06M | 2.901M | 1.166M | - |
| Net Debt | 94.538M | 22.571M | -87.305M | -31.209M | -10.287M |
| Short Term Debt | 92.834M | 132.374M | 75.588M | 2.55M | 13.846M |
| Short Long Term Debt | 88.194M | 128.025M | 72.281M | 2.55M | 13.846M |
| Short Long Term Debt Total | 195.677M | 255.16M | 108.912M | 6.679M | 17.051M |
| Other Stockholder Equity | - | 8.541M | 8.544M | 11.017M | 1.214M |
| Property Plant Equipment | - | - | 86.509M | 53.47M | 32.15M |
| Total Current Assets | 418.804M | 507.493M | 336.159M | 76.652M | 42.208M |
| Long Term Investments | 1.922M | 42.565M | 2.565M | 3.141M | 39.91M |
| Short Term Investments | 0.187M | 0.205M | 0.33M | 0.376M | 0.177M |
| Net Receivables | 170.778M | 129.95M | 37.531M | 15.357M | 8.903M |
| Long Term Debt | 82.202M | 99.684M | 11.953M | 0.629M | 0.436M |
| Inventory | 106.291M | 126.498M | 67.879M | 22.202M | 5.79M |
| Accounts Payable | 78.44M | 126.067M | 64.472M | 18.622M | 4.935M |
| Accumulated Other Comprehensive Income | 15.949M | 2.388M | 2.388M | 2.388M | 2.388M |
| Non Currrent Assets Other | 22.654M | - | 0.001M | - | - |
| Non Current Assets Total | 367.81M | 450.514M | 350.165M | 249.618M | 240.025M |
| Capital Lease Obligations | 25.281M | 27.451M | 24.678M | 3.5M | 2.769M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -142.497M | -1.246M | -0.626M | 2.272M | -6.566M |
| Total Cashflows From Investing Activities | - | -65.21M | -22.763M | -26.087M | -7.955M |
| Total Cash From Financing Activities | 120.446M | 203.057M | 25.289M | 66.166M | 10.614M |
| Net Income | 43.749M | 7.295M | -36.04M | -2.996M | -12.798M |
| Change In Cash | 36.372M | 158.33M | 10.55M | 21.957M | 1.186M |
| Begin Period Cash Flow | 196.217M | 37.888M | 27.338M | 3.416M | 2.23M |
| End Period Cash Flow | 232.589M | 196.218M | 37.888M | 25.373M | 3.416M |
| Total Cash From Operating Activities | 51.267M | 25.02M | 7.803M | -4.013M | -1.486M |
| Depreciation | 11.699M | 7.393M | 3.253M | 0.023M | 0.01M |
| Other Cashflows From Investing Activities | - | -23.499M | -0.04M | -0.6M | -1.296M |
| Dividends Paid | 0M | - | - | - | - |
| Change To Inventory | -75.988M | -17.888M | -16.175M | 3.029M | 3.029M |
| Sale Purchase Of Stock | - | - | - | - | - |
| Other Cashflows From Financing Activities | 246.19M | 83.957M | -12.152M | 3.883M | 8.73M |
| Capital Expenditures | 19.742M | 14.029M | 20.841M | 0.001M | 0.093M |
| Change In Working Capital | -3.018M | -1.654M | -4.121M | -0.669M | 0.93M |
| Other Non Cash Items | -10.163M | -5.907M | -2.36M | -56.245M | 1.861M |
| Free Cash Flow | 31.525M | 10.991M | -13.038M | -4.014M | -1.579M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Amplify Alternative Harvest ETF | 2 years ago | 325741 |
| 2. | KSM Active IL Equities Large&Mid Cap | 2 years ago | 66925 |
| 3. | I.B.I 85/15 | 2 years ago | 63000 |
| 4. | I.B.I 70/30 | 2 years ago | 61213 |
| 5. | KSM TA Large & Mid Cap IL | 2 years ago | 57173 |
| 6. | Etzioni Flexible | 2 years ago | 55668 |
| 7. | Cambria Cannabis ETF | 2 years ago | 54681 |
| 8. | Etzioni Israel Equity IL | 2 years ago | 51440 |
| 9. | Sela Stocks IL | 2 years ago | 42464 |
| 10. | I.B.I 80/20 | 2 years ago | 37419 |
| 11. | KSM Yeter IL | 2 years ago | 36620 |
| 12. | MTF TR TA-Growth | 2 years ago | 32591 |
| 13. | Target 10/90 IL | 2 years ago | 24776 |
| 14. | Target 80/20 IL | 2 years ago | 23000 |
| 15. | KSM Active Flexible | 2 years ago | 22142 |
| 16. | Fidelity Nasdaq Composite Index | 2 years ago | 19375 |
| 17. | KSM Active Managed Portfolio IL | 2 years ago | 16142 |
| 18. | KSM Active 80-20 IL | 2 years ago | 13391 |
| 19. | I.B.I GUY 75/25 IL | 2 years ago | 11501 |
| 20. | KSM Active 80/20 IL | 2 years ago | 11485 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...